Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.

Vollenberg R, Jouni R, Norris PAA, Burg-Roderfeld M, Cooper N, Rummel MJ, Bein G, Marini I, Bayat B, Burack R, Lazarus AH, Bakchoul T, Sachs UJ.

Haematologica. 2019 Jun;104(6):1237-1243. doi: 10.3324/haematol.2018.211086. Epub 2019 Mar 28.

2.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP.

Haematologica. 2019 Feb 21. pii: haematol.2018.207266. doi: 10.3324/haematol.2018.207266. [Epub ahead of print]

3.

An evolving technology for an evolving disease: A commentary on NGS-based MRD evaluation in B-ALL.

Fries C, Burack R.

Leuk Res. 2019 Jan;76:105-106. doi: 10.1016/j.leukres.2018.11.009. Epub 2018 Nov 16. No abstract available.

PMID:
30473329
4.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

5.

Ipilimumab-Induced Neutropenia in Melanoma.

Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D.

J Investig Med High Impact Case Rep. 2016 Aug 9;4(3):2324709616661835. doi: 10.1177/2324709616661835. eCollection 2016 Jul-Sep.

6.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.

J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.

7.

Increased numbers of CD23(+) CD21(hi) Bin-like B cells in human reactive and rheumatoid arthritis lymph nodes.

Kuzin II, Kates SL, Ju Y, Zhang L, Rahimi H, Wojciechowski W, Bernstein SH, Burack R, Schwarz EM, Bottaro A.

Eur J Immunol. 2016 Jul;46(7):1752-7. doi: 10.1002/eji.201546266. Epub 2016 May 6.

8.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP.

Mol Immunol. 2016 Feb;70:13-23. doi: 10.1016/j.molimm.2015.12.007. Epub 2015 Dec 12.

PMID:
26690706
9.

Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.

Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV, Popova L, Kaminiski D, Fucile CF, Albizua I, Kyu S, Chiang KY, Bradley KT, Burack R, Slifka M, Hammarlund E, Wu H, Zhao L, Walsh EE, Falsey AR, Randall TD, Cheung WC, Sanz I, Lee FE.

Immunity. 2015 Jul 21;43(1):132-45. doi: 10.1016/j.immuni.2015.06.016. Epub 2015 Jul 14.

10.

Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.

Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, Deshaies RJ, Land H, Zhao J.

Oncotarget. 2015 Jun 20;6(17):14796-813.

11.

Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells.

Aslam R, Segel GB, Burack R, Spence SA, Speck ER, Guo L, Semple JW.

Br J Haematol. 2016 Apr;173(1):159-60. doi: 10.1111/bjh.13567. Epub 2015 Jun 24. No abstract available.

PMID:
26104295
12.

Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.

Vajpayee N, Burack R, Wang D, Hutchison RE, Gajra A.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):159-63. doi: 10.1016/j.clml.2014.09.010. Epub 2014 Oct 2.

PMID:
25458080
13.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH.

J Clin Oncol. 2014 Jan 1;32(1):44-50. doi: 10.1200/JCO.2012.46.8793. Epub 2013 Sep 16.

14.

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI.

Ann Oncol. 2013 Jun;24(6):1587-93. doi: 10.1093/annonc/mdt070. Epub 2013 Mar 15.

15.

Homocysteine and reclassification of cardiovascular disease risk.

Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, Jacob S, Afonso L.

J Am Coll Cardiol. 2011 Aug 30;58(10):1025-33. doi: 10.1016/j.jacc.2011.05.028.

16.

Relevance of IgVH gene somatic hypermutation and interphase cytogenetics in lymphomatous presentation of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Yeung CC, Powers ML, Nguyen TD, Kreisel F, Frater JL, Zehnbauer BA, Burack R, Hassan A.

Int J Surg Pathol. 2011 Oct;19(5):563-9. doi: 10.1177/1066896911406918. Epub 2011 May 1.

PMID:
21536543
17.

Combined core needle biopsy and fine-needle aspiration with ancillary studies correlate highly with traditional techniques in the diagnosis of nodal-based lymphoma.

Amador-Ortiz C, Chen L, Hassan A, Frater JL, Burack R, Nguyen TT, Kreisel F.

Am J Clin Pathol. 2011 Apr;135(4):516-24. doi: 10.1309/AJCP3WZ8ZDRJQDOU.

PMID:
21411774
18.

The cost of health care services provided to women enrolled in a community-based breast and cervical cancer screening program.

Burack R, Latafa J.

J Health Care Poor Underserved. 2009 Aug;20(3):713-20. doi: 10.1353/hpu.0.0171.

PMID:
19648699
19.

Clarifying the principles of cost-effectiveness analyses.

Burack RC.

Ann Intern Med. 2009 Jul 21;151(2):142; author reply 142. No abstract available.

PMID:
19620170
20.

Telephone reminders increase re-screening in a county breast screening program.

Goel A, George J, Burack RC.

J Health Care Poor Underserved. 2008 May;19(2):512-21. doi: 10.1353/hpu.0.0025.

PMID:
18469422
21.

Life expectancy and colorectal cancer screening.

Burack RC.

Ann Intern Med. 2007 May 15;146(10):758; author reply 758-9. No abstract available.

PMID:
17502641
22.

The association between the pre-diagnosis mammography screening interval and advanced breast cancer.

Goel A, Littenberg B, Burack RC.

Breast Cancer Res Treat. 2007 May;102(3):339-45. Epub 2006 Aug 23.

23.

Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.

Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A.

J Clin Oncol. 2005 Aug 20;23(24):5718-27. Epub 2005 Jul 11.

PMID:
16009945
24.

The effect of adding Pap smear information to a mammography reminder system in an HMO: results of randomized controlled trial.

Burack RC, Gimotty PA, Simon M, Moncrease A, Dews P.

Prev Med. 2003 May;36(5):547-54.

PMID:
12689799
25.

Exercise intensity and risk of coronary heart disease.

Burack R.

JAMA. 2003 Jan 22-29;289(4):419; author reply 419-20. No abstract available.

PMID:
12533106
26.
27.

The effect of patient reminders on the use of screening mammography in an urban health department primary care setting.

Simon MS, Gimotty PA, Moncrease A, Dews P, Burack RC.

Breast Cancer Res Treat. 2001 Jan;65(1):63-70.

PMID:
11245341
28.

Follow-up among women with an abnormal mammogram in an HMO: is it complete, timely, and efficient?

Burack RC, Simon MS, Stano M, George J, Coombs J.

Am J Manag Care. 2000 Oct;6(10):1102-13.

29.

Effectiveness of computerized reminders in ambulatory care.

Burack RC, Gimotty PA.

JAMA. 2000 Dec 13;284(22):2872-3. No abstract available.

PMID:
11147980
30.
32.

Mammography use among women as a function of age and patient involvement in decision-making.

Burack RC, George J, Gurney JG.

J Am Geriatr Soc. 2000 Jul;48(7):817-21.

PMID:
10894323
33.
34.
35.

Teenage sexual behaviour: attitudes towards and declared sexual activity.

Burack R.

Br J Fam Plann. 1999 Jan;24(4):145-8.

PMID:
10023100
36.

Health status and mammography use among older women.

Burack RC, Gurney JG, McDaniel AM.

J Gen Intern Med. 1998 Jun;13(6):366-72.

37.

How reminders given to patients and physicians affected pap smear use in a health maintenance organization: results of a randomized controlled trial.

Burack RC, Gimotty PA, George J, McBride S, Moncrease A, Simon MS, Dews P, Coombs J.

Cancer. 1998 Jun 15;82(12):2391-400.

PMID:
9635532
38.

Factors affecting participation in a mammography screening program among members of an urban Detroit health maintenance organization.

Simon MS, Gimotty PA, Coombs J, McBride S, Moncrease A, Burack RC.

Cancer Detect Prev. 1998;22(1):30-8.

PMID:
9466046
40.

Predictors of mammography use in the past year among elderly women.

Persky NW, Burack R.

J Aging Health. 1997 Aug;9(3):334-54.

41.
42.

Fifteen years of a videotape review program for internal medicine and medicine-pediatrics residents.

Edwards A, Tzelepis A, Klingbeil C, Melgar T, Speece M, Schubiner H, Burack R.

Acad Med. 1996 Jul;71(7):744-8.

PMID:
9158342
43.

The primary care pathway to mammography: a long and winding road.

Burack RC.

J Gen Intern Med. 1995 Jun;10(6):349-50. No abstract available.

PMID:
7562127
44.
45.

Patterns of use of mammography among inner-city Detroit women: contrasts between a health department, HMO, and private hospital.

Burack RC, Gimotty PA, Stengle W, Warbasse L, Moncrease A.

Med Care. 1993 Apr;31(4):322-34.

PMID:
8464249
46.

The challenging case conference: an integrated approach to resident education and support.

Burack RC, Butler R, Frankel R, Kulesza G, Edwards A, Speece M, Beckman H.

J Gen Intern Med. 1991 Jul-Aug;6(4):355-9. No abstract available.

PMID:
1890509
47.

Therapeutic substitution and formulary systems.

Burack R.

Ann Intern Med. 1990 Oct 15;113(8):640. No abstract available.

PMID:
2400175
48.

Detroit's avoidable mortality project: breast cancer control for inner-city women.

Burack RC, Gimotty PA, Stengle W, Eckert D, Warbasse L, Moncrease A.

Public Health Rep. 1989 Nov-Dec;104(6):527-35.

49.

The acceptance and completion of mammography by older black women.

Burack RC, Liang J.

Am J Public Health. 1989 Jun;79(6):721-6.

50.

Barriers to clinical preventive medicine.

Burack RC.

Prim Care. 1989 Mar;16(1):245-50. Review.

PMID:
2649905

Supplemental Content

Loading ...
Support Center